Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

1362103

USP

Levofloxacin

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

Levofloxacin hemihydrate

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C18H20FN3O4 · 0.5H2O
Número CAS:
138199-71-0
Peso molecular:
370.38
Número MDL:
MFCD07772024
Código UNSPSC:
41116107
ID de substância PubChem:
329750045
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

levofloxacin

fabricante/nome comercial

USP

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O

InChI

1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

chave InChI

SUIQUYDRLGGZOL-RCWTXCDDSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Aplicação

Levofloxacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Levofloxacin Tablets
  • Levofloxacin Oral Solution

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1362114

Levofloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1362125

Levofloxacin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1362136

Levofloxacin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1362169

Levofloxacin Related Compound F, United States Pharmacopeia (USP) Reference Standard

1362158

Levofloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

Y0002085

Levofloxacin hemihydrate, European Pharmacopoeia (EP) Reference Standard

Y0002084

Levofloxacin impurity F, European Pharmacopoeia (EP) Reference Standard

Y0002089

Levofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2229

Levofloxacin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2230

Levofloxacin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Danger

Frases de perigo

H302,H317,H334

Classificações de perigo

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 1

1 of 1

Ofloxacin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1168

Ofloxacin

R Davis et al.
Drugs, 47(4), 677-700 (1994-04-01)
Levofloxacin, an oral fluoroquinolone antibacterial agent, is the optical S-(-) isomer of ofloxacin. In vitro it is generally twice as potent as ofloxacin. Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate activity against anaerobes. Drug
Analysis and Standardization of Levofloxacin Substance.
Sedova, M. K., et al.
Pharmaceutical Chemistry Journal, 47.11, 620-626 (2014)
Kyung Eun Han et al.
American journal of ophthalmology, 157(6), 1144-1150 (2014-02-25)
To evaluate dry eye and meibomian gland dysfunction after cataract surgery. Prospective observational case series. We studied 58 eyes of 48 patients who underwent phacoemulsification and evaluated them preoperatively and at 1 month and 3 months postoperatively. Ocular symptom scores
Lixian He et al.
Anti-cancer drugs, 26(3), 359-362 (2014-12-09)
This pilot study assesses the safety and efficacy of once-daily, oral levofloxacin monotherapy in Chinese patients with low-risk febrile neutropenia. In this prospective, single-arm, open-label, multicenter clinical trial, 46 adult Chinese patients with solid tumors and low-risk febrile neutropenia were
Sabine Schuster et al.
Antimicrobial agents and chemotherapy, 58(11), 6870-6878 (2014-09-04)
Efflux is an important mechanism of bacterial multidrug resistance (MDR), and the inhibition of MDR pumps by efflux pump inhibitors (EPIs) could be a promising strategy to overcome MDR. 1-(1-Naphthylmethyl)-piperazine (NMP) and phenylalanine-arginine-β-naphthylamide (PAβN) are model EPIs with activity in
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica